Presentation of GA-map® by Genetic Analysis sparks great interest at xMAP® Connect EMEA in Amsterdam
OSLO, NORWAY, November 16, 2023: Microbiome DX company Genetic Analysis AS (“GA” or “the Company”) announces today that the Company recently presented its proprietary microbiome testing platform GA-map® at xMAP® Connect EMEA, a conference by Luminex Corporation – a DiaSorin Company. The presentation was about how GA's microbiome testing platform works together with Luminex's xMAP® technology, and the interest in GA-map® was strong. During the conference, several valuable contacts were established that the Company will now follow up on.
Genetic Analysis recently participated in xMAP® Connect EMEA, an industry conference organized by the international biotech company Luminex Corporation. The event took place between November 8-9 in Amsterdam, the Netherlands, and the purpose was to gather industry leaders and Luminex's xMAP® users, share experiences, present the latest updates on their projects, and establish dialogues for new research collaborations.
During the conference, GA presented the latest news about the Company's microbiome testing platform GA-map®, focusing on how the platform works together with Luminex Corporation's proprietary xMAP® technology offering standardized high-plex microbiome tests. Interest in the Company's microbiome testing platform was strong, and it attracted several listeners.
Detlef Janke, Commercial Director for Genetic Analysis, comments:
“Our participation at the conference was a great opportunity for us to promote our unique microbiome testing platform, GA-map®, and show how it complements Luminex Corporation's xMAP® technology, which thousands of laboratories use today. The event has also provided us with rewarding discussions with industry leaders and Luminex's xMAP® users in microbiome diagnostics, which we will now follow up on.”
A link to the presentation can be found here: https://www.youtube.com/watch?v=q_rlFSxDM6Q
For further information, please contact:
Ronny Hermansen, Chief Executive Officer
E-mail: rh@genetic-analysis.com
About Genetic Analysis:
Genetic Analysis AS (GA) is a science-based diagnostic company and pioneer in the human microbiome field with more than 15 years of expertise in research and product development. The unique GA-map® platform is based on a pre-determined multiplex targets approach specialized for simultaneous analysis of a large number of bacteria in one reaction. The test results are generated by utilizing the clinically validated cutting edge GA-map® software algorithm. This enables immediate results without the need for further bioinformatics work. GA’s vision is to become the leading company for standardized gut microbiota testing worldwide, and GA is committed to help unlocking and restoring the human microbiome through its state-of-the-art technology. GA employs a team of highly qualified employees with scientific backgrounds and competence in bioinformatics, molecular biology, and bioengineering.
For more general information: www.genetic-analysis.com
Stay updated on GA and sign up for more investor-related information: https://www.genetic-analysis.com/subscriptions/
Interested in reading more about GA's products? Please visit ga-map.com